Logo image of BTI.CA

BIOASIS TECHNOLOGIES INC (BTI.CA) Stock Fundamental Analysis

Canada - TSX Venture Exchange - TSX-V:BTI - CA09064N1033 - Common Stock

0.005 CAD
0 (0%)
Last: 3/18/2024, 7:00:00 PM
Fundamental Rating

0

We assign a fundamental rating of 0 out of 10 to BTI. BTI was compared to 23 industry peers in the Biotechnology industry. BTI has a bad profitability rating. Also its financial health evaluation is rather negative. BTI is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year BTI has reported negative net income.
  • In the past year BTI has reported a negative cash flow from operations.
BTI.CA Yearly Net Income VS EBIT VS OCF VS FCFBTI.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 0 -2M -4M

1.2 Ratios

  • The Return On Assets of BTI (-163.11%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -163.11%
ROE N/A
ROIC N/A
ROA(3y)-180.01%
ROA(5y)-234.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BTI.CA Yearly ROA, ROE, ROICBTI.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 500 -500 -1K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for BTI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BTI.CA Yearly Profit, Operating, Gross MarginsBTI.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -2K -4K -6K -8K

More info and screens

0

2. Health

2.1 Basic Checks

  • BTI does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • BTI has more shares outstanding than it did 1 year ago.
  • The debt/assets ratio for BTI is higher compared to a year ago.
BTI.CA Yearly Shares OutstandingBTI.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M
BTI.CA Yearly Total Debt VS Total AssetsBTI.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 1M 2M 3M

2.2 Solvency

  • Based on the Altman-Z score of -41.85, we must say that BTI is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -41.85, BTI is doing worse than 70.83% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -41.85
ROIC/WACCN/A
WACC6.78%
BTI.CA Yearly LT Debt VS Equity VS FCFBTI.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 1M -1M -2M -3M

2.3 Liquidity

  • A Current Ratio of 0.11 indicates that BTI may have some problems paying its short term obligations.
  • BTI has a worse Current ratio (0.11) than 87.50% of its industry peers.
  • BTI has a Quick Ratio of 0.11. This is a bad value and indicates that BTI is not financially healthy enough and could expect problems in meeting its short term obligations.
  • BTI's Quick ratio of 0.11 is on the low side compared to the rest of the industry. BTI is outperformed by 83.33% of its industry peers.
Industry RankSector Rank
Current Ratio 0.11
Quick Ratio 0.11
BTI.CA Yearly Current Assets VS Current LiabilitesBTI.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 1M 2M 3M

More info and screens

2

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 21.43% over the past year.
  • BTI shows a strong growth in Revenue. In the last year, the Revenue has grown by 613.97%.
  • BTI shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -40.66% yearly.
EPS 1Y (TTM)21.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)613.97%
Revenue growth 3Y-70.17%
Revenue growth 5Y-40.66%
Sales Q2Q%294.75%

3.2 Future

  • BTI is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -5.27% yearly.
  • Based on estimates for the next years, BTI will show a very negative growth in Revenue. The Revenue will decrease by -25.99% on average per year.
EPS Next Y-16.67%
EPS Next 2Y-8.01%
EPS Next 3Y-5.27%
EPS Next 5YN/A
Revenue Next Year215.79%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BTI.CA Yearly Revenue VS EstimatesBTI.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M
BTI.CA Yearly EPS VS EstimatesBTI.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 0 0.02 -0.02 -0.04 -0.06

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for BTI. In the last year negative earnings were reported.
  • Also next year BTI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BTI.CA Price Earnings VS Forward Price EarningsBTI.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BTI.CA Per share dataBTI.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.02 -0.04 -0.06

4.3 Compensation for Growth

  • A cheap valuation may be justified as BTI's earnings are expected to decrease with -5.27% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.01%
EPS Next 3Y-5.27%

More info and screens

0

5. Dividend

5.1 Amount

  • BTI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOASIS TECHNOLOGIES INC

TSX-V:BTI (3/18/2024, 7:00:00 PM)

0.005

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A
Earnings (Next)01-26
Inst Owners0.08%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap397.07K
Revenue(TTM)269.38K
Net Income(TTM)-2.88M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.47
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.04
EYN/A
EPS(NY)-0.07
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0
BVpS-0.03
TBVpS-0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -163.11%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-180.01%
ROA(5y)-234.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.11
Quick Ratio 0.11
Altman-Z -41.85
F-Score3
WACC6.78%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y-16.67%
EPS Next 2Y-8.01%
EPS Next 3Y-5.27%
EPS Next 5YN/A
Revenue 1Y (TTM)613.97%
Revenue growth 3Y-70.17%
Revenue growth 5Y-40.66%
Sales Q2Q%294.75%
Revenue Next Year215.79%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
EBIT growth 1Y14.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-719.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-719.99%
OCF growth 3YN/A
OCF growth 5YN/A

BIOASIS TECHNOLOGIES INC / BTI.CA FAQ

What is the fundamental rating for BTI stock?

ChartMill assigns a fundamental rating of 0 / 10 to BTI.CA.


What is the valuation status of BIOASIS TECHNOLOGIES INC (BTI.CA) stock?

ChartMill assigns a valuation rating of 0 / 10 to BIOASIS TECHNOLOGIES INC (BTI.CA). This can be considered as Overvalued.


How profitable is BIOASIS TECHNOLOGIES INC (BTI.CA) stock?

BIOASIS TECHNOLOGIES INC (BTI.CA) has a profitability rating of 0 / 10.


What is the earnings growth outlook for BIOASIS TECHNOLOGIES INC?

The Earnings per Share (EPS) of BIOASIS TECHNOLOGIES INC (BTI.CA) is expected to decline by -16.67% in the next year.